 Aduro Biotech, Inc. ADRO, a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes STING and A Proliferation Inducing Ligand APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company earned a 10.0 million development milestone payment under its worldwide licensing agreement with Merck known as MSD outside the United States and Canada for the initiation of a Phase 2 clinical trial of MK-5890, an anti-CD27 agonist, in non-small cell lung cancer NSCLC. We are thrilled Merck is continuing to advance MK-5890 through development with the initiation of a Phase 2 clinical trial in NSCLC, said Andrea van Elsas, Ph.D., chief scientific officer of Aduro. 